Select country set
Menu Shopping cart 0,00 Search
Manufactured by BioVendor

TACI (TNFRSF13B) Human E. coli

  • Regulatory status:RUO
  • Type:Recombinant protein
  • Source:E. coli
  • Other names:TNFRSF13B, Transmembrane activator and CAML interactor, TNFRSF13B
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price

RBG10302005 5 µg
RBG10302020 20 µg
RBG10302100 100 μg
PubMed Product Details
Technical Data


Recombinant protein


TACI, a member of the TNF Receptor superfamily, is expressed in the small intestine, spleen, thymus, peripheral blood leukocytes, activated T cells, and resting B cells. TACI can bind to both APRIL and BAFF, stimulate the activation of transcription factors NF-κB and AP-1, and can mediate the calcineurin-dependent activation of NF-AT (nuclear-factor of activated T cells). TACI also plays a key role in the stimulation of B and T cell function. Soluble TACI inhibits APRIL-stimulated proliferation of primary B cells by blocking the binding of APRIL to the membrane-anchored TACI receptor. Recombinant Human TACI is a soluble 159 amino acid polypeptide (17.8 kDa) comprising the TNFR homologous, cysteine-rich extracellular domain of the TACI protein.

Amino Acid Sequence



E. coli



Biological Activity

Determined by its ability to block human BAFF induced T2B cell survival using a concentration range of 1.0–3.0 µg/ml.


Endotoxin level is <0.1 ng/μg of protein (<1EU/μg).


Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.1–1.0 mg/ml. Do not vortex. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at-20°C to –80°C.




Research topic

Immune Response, Infection and Inflammation, Oncology

Related Products Docs